Amazing Spider-Man & Venom: Venom Inc. Omega Spoils Itself

by Drew Baumgartner

Venom Inc Omega

This article contains SPOILERS. If you haven’t read the issue yet, proceed at your own risk!

How do we feel about Marvel’s “alpha” and “omega” strategy to crossovers? That is, mostly embedding the crossover in already-running monthlies, reducing the event series to just the first and last chapters of the story. They’re harder to skip by design — where you might be able to simply ignore an entire event series, you might be pulled into a crossover if a book you’re following is participating — but that can be frustrating to otherwise disinterested readers. Another downside that I hadn’t considered is that the stakes of an omega issue are kind of necessarily neutered — their inessential nature means they lack the ballast to make any changes that would be too earth-shattering to its participating series. Any big changes must have already happened in the series it would most effect, leaving the omega to tie up the loose ends with as little disruption to the status quo as possible. I don’t love to lead with these kind of meta-critiques of an issue (honestly, most superhero story arcs wrap up with the same kind of predictable return-to-normal), but Amazing Spider-Man & Venom: Venom Inc. Omega seems determined to keep it at the forefront of my mind, stymying any tension at every chance it gets. Continue reading

Heroes and Villains Alike Assemble Their Armies in Amazing Spider-Man 793

by Spencer Irwin

Amazing Spider-Man 793

This article contains SPOILERS. If you haven’t read the issue yet, proceed at your own risk!

By the end of The Amazing Spider-Man 793 — the fourth installment of Dan Slott, Mike Costa, and Ryan Stegman’s “Venom Inc.” crossover — the many various players that have filled out this story have essentially grouped into two opposing sides. What’s interesting is the way these factions differ from each other. Continue reading

Middle-Chapter Blues in Amazing Spider-Man 792

by Spencer Irwin

This article contains SPOILERS. If you haven’t read the issue yet, proceed at your own risk!

The middle chapters of multi-issue storylines sometimes suffer a bit. They’re not a beginning, they’re not an ending — sometimes all they can do is move a few plot points forward, hopefully in the most entertaining manner possible. The Amazing Spider-Man 792, the second installment of Dan Slott, Mike Costa, and Ryan Stegman’s “Venom Inc” crossover, is decidedly one of those middle chapters, but even in comparison to other middle chapters it suffers a bit. Continue reading

Everybody Wants to be Venom in the Amazing Spider-Man & Venom: Venom Inc. Alpha

by Spencer Irwin

This article contains SPOILERS. If you haven’t read the issue yet, proceed at your own risk!

Legacy heroes (and villains!) always present a bit of a conundrum. The inheritors of the mantles tend to bring much needed diversity and fresh perspectives to their stories and quickly amass fanbases, but of course the original characters have lifelong fans who aren’t happy to see their beloved heroes pushed aside, even temporarily. To me, the obvious solution has always been to have multiple characters share names and roles: why not have two Captains America or two Hawkeyes, four Flashes or a million Green Lanterns?

Both this conflict and this solution seem to be the core of Dan Slott, Mike Costa, and Ryan Stegman’s new crossover event, Venom Inc. It’s a story that finds the various men who have been Venom fighting over their right to symbiote, and which, at least for the moment, seems to be finding great joy in including as many Venoms as possible. Continue reading